Prostate cancer and PSMA-targeted imaging
Clinical research in prostate cancer is centered on advanced management of metastatic hormone-sensitive disease, with interest in PSMA-positive patient populations and treatment selection. The portfolio also includes work on the use of PSMA-PET and mpMRI to identify and define clinically relevant intraprostatic lesions.
- Radioligand therapy in metastatic prostate cancer
- Androgen receptor-targeted therapy comparisons
- PSMA-PET and mpMRI lesion detection
These studies reflect a focus on improving disease control and refining diagnostic precision in prostate oncology.
Glaucoma and optic nerve disease
Research activity also covers open-angle glaucoma and PEX glaucoma, with attention to newly diagnosed patients who already show visual field loss and optic nerve or nerve fiber damage. The studies examine progression under different treatment strategies in routine clinical care.
- Open-angle glaucoma
- PEX glaucoma
- Perimetric progression monitoring
The therapeutic emphasis is on preserving vision through optimized management of glaucomatous disease.
Vision preservation and pressure-lowering treatment
Within glaucoma care, the sponsor supports comparisons of treatment intensity, including monotherapy, combination regimens, and laser trabeculoplasty. The clinical interest lies in slowing functional decline and preventing further damage in patients at risk of progressive visual impairment.
- Medical therapy for intraocular pressure control
- Combination drop therapy
- Laser trabeculoplasty
These trials address treatment choices in early and established glaucoma management.
Diagnostic accuracy in urologic oncology
The sponsor’s imaging research includes comparison of molecular imaging and magnetic resonance imaging for detecting and mapping prostate lesions. A key area of interest is the alignment of imaging findings with histopathologic validation to better characterize clinically important disease regions.
- PSMA-PET assessment
- mpMRI evaluation
- Histopathologic correlation
This work supports more precise localization of high-risk prostate cancer.
